- Michael Weingarten, Director, NCI SBIR Development Center
- Christie Canaria, Program Director, NCI SBIR Development Center
1:00 PM – 2:00 PM – Presentation: NCI SBIR/STTR Overview and Initiatives
2:00 PM –2:30 PM – Q&A
If you have any questions about the webinar, please contact BIO: (firstname.lastname@example.org) or NCI SBIR: (email@example.com).
Michael Weingarten | Director, SBIR Development Center, National Cancer Institute
Michael Weingarten is the Director for the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute in Bethesda, MD. In this role, Mr. Weingarten leads a team of nine Program Directors who manage all aspects of the NCI SBIR & STTR Programs including a portfolio of $160M in grants and contracts annually. The SBIR & STTR programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. Mr. Weingarten has implemented a set of key initiatives for optimizing the performance of the NCI SBIR Program at the NIH. These include the establishment of a new model at the NCI for managing the program – the SBIR Development Center.
Under Mr. Weingarten’s leadership, the NCI SBIR Development Center has launched a range of new initiatives to facilitate the success of small businesses developing cancer-related technologies. Recent initiatives include the launch of the NIH I-Corps™ pilot program in which teams of budding entrepreneurs engage in a hypothesis-driven approach to validate their proposed business models by conducting over 100 interviews with potential customers. Companies adjust their strategies based on direct customer feedback and analyze the information they collect to determine if there is a product/market fit. Other NCI SBIR initiatives introduced under Mr. Weingarten’s leadership include the NCI SBIR Investor Forums, the NCI SBIR Phase II Bridge Award, and the workshop titled Federal Resources to Accelerate Commercialization (FRAC). Thus far, NCI SBIR has held three investor forums that in total have facilitated the closing of investment deals with NCI-funded SBIR companies valued at over $300M. The NCI SBIR Phase II Bridge Award, which was launched in 2009, incentivizes partnerships between NIH’s SBIR Phase II awardees and third-party investors and/or strategic partners to help small businesses bridge the funding gap between the end of their SBIR Phase II awards and the next round of financing needed to advance a promising cancer therapy or imaging technology.
Christie Canaria, Ph.D. | Program Manager, SBIR Development Center, National Cancer Institute
Dr. Christie Canaria is a Program Manager in the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute (NCI). She provides programmatic support to small businesses applying to the SBIR and STTR programs and has areas of expertise in biological imaging, biosensors, and nanotechnology. Dr. Canaria is a central figure in planning special center initiatives, conducting outreach activities, and coordinating communications. In 2014, she played a leading role in launching the Innovation Corps (I-Corps™) at NIH Pilot, a program designed to support training to help project teams at NIH-funded small businesses overcome key obstacles along the path of innovation and commercialization.
In 2013, Dr. Canaria was awarded the AAAS Science & Technology Policy Fellowship and began science policy work in Washington, DC. Previously, she managed an optical microscopy facility at DOE Lawrence Berkeley National Laboratory as an imaging expert and neurobiologist; she was also a coordinator and imaging expert at the Caltech Biological Imaging Center where she developed advanced, multi-dimensional and time-lapse confocal imaging techniques. Dr. Canaria also worked in industry, expanding and optimizing surface chemistry and imaging processes for genome sequencing technologies. Dr. Canaria earned her Ph.D. in Chemistry from the California Institute of Technology and a B.S. in Chemistry from the University of California, San Diego.